141 related articles for article (PubMed ID: 37158306)
1. Detection of serum M-protein in acetonitrile precipitates by MALDI-TOF mass spectrometry: A novel, low-cost methodology.
Mehra N; Gopisetty G; Subramani J; Dhanasekar S; Rajamanickam A; Perumal Kalaiyarasi J; Karunakaran P; Kannan K; Rajaraman S; Rajkumar T
Ann Clin Biochem; 2023 Sep; 60(5):339-348. PubMed ID: 37158306
[TBL] [Abstract][Full Text] [Related]
2. Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry.
Sepiashvili L; Kohlhagen MC; Snyder MR; Willrich MAV; Mills JR; Dispenzieri A; Murray DL
Clin Chem; 2019 Aug; 65(8):1015-1022. PubMed ID: 31171529
[TBL] [Abstract][Full Text] [Related]
3. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
Eveillard M; Korde N; Ciardiello A; Diamond B; Lesokhin A; Mailankody S; Smith E; Hassoun H; Hultcrantz M; Shah U; Lu S; Salcedo M; Werner K; Rispoli J; Mastey D; Landgren O; Thoren K
Clin Chim Acta; 2021 May; 516():136-141. PubMed ID: 33545108
[TBL] [Abstract][Full Text] [Related]
4. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
[TBL] [Abstract][Full Text] [Related]
5. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
Moore LM; Cho S; Thoren KL
Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
[TBL] [Abstract][Full Text] [Related]
6. Rapid detection of serum free light chains by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Kaya ZZ; Serdar M; Aksungar F; Kilercik M; Serteser M; Baykal AT
Eur J Mass Spectrom (Chichester); 2023 Apr; 29(2):132-140. PubMed ID: 36734073
[No Abstract] [Full Text] [Related]
7. Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.
Kohlhagen MC; Barnidge DR; Mills JR; Stoner J; Gurtner KM; Liptac AM; Lofgren DI; Vanderboom PM; Dispenzieri A; Katzmann JA; Willrich MA; Snyder MR; Murray DL
Clin Chem; 2016 Oct; 62(10):1345-52. PubMed ID: 27515443
[TBL] [Abstract][Full Text] [Related]
8. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.
Barnidge DR; Dasari S; Botz CM; Murray DH; Snyder MR; Katzmann JA; Dispenzieri A; Murray DL
J Proteome Res; 2014 Mar; 13(3):1419-27. PubMed ID: 24467232
[TBL] [Abstract][Full Text] [Related]
9. Characterizing M-protein light chain glycosylation via mass spectrometry.
Miller ID; Kohlhagen MC; Ladwig PM; Dasari S; Kumar S; Dispenzieri A; Willrich MAV; Murray DL
Clin Biochem; 2022; 109-110():11-16. PubMed ID: 36113628
[TBL] [Abstract][Full Text] [Related]
10. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.
Murray D; Kumar SK; Kyle RA; Dispenzieri A; Dasari S; Larson DR; Vachon C; Cerhan JR; Rajkumar SV
Blood Cancer J; 2019 Dec; 9(12):102. PubMed ID: 31836698
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
Katzmann JA; Abraham RS; Dispenzieri A; Lust JA; Kyle RA
Clin Chem; 2005 May; 51(5):878-81. PubMed ID: 15774572
[TBL] [Abstract][Full Text] [Related]
12. Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry.
Thoren KL; Eveillard M; Chan P; Doddi S; Cho S; Murata K
Clin Biochem; 2020 Mar; 77():57-61. PubMed ID: 31884198
[TBL] [Abstract][Full Text] [Related]
13. Screening panels for detection of monoclonal gammopathies.
Katzmann JA; Kyle RA; Benson J; Larson DR; Snyder MR; Lust JA; Rajkumar SV; Dispenzieri A
Clin Chem; 2009 Aug; 55(8):1517-22. PubMed ID: 19520758
[TBL] [Abstract][Full Text] [Related]
14. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to detect monoclonal immunoglobulin light chains in serum and urine.
Barnidge DR; Krick TP; Griffin TJ; Murray DL
Rapid Commun Mass Spectrom; 2015 Nov; 29(21):2057-60. PubMed ID: 26443406
[TBL] [Abstract][Full Text] [Related]
15. Serum free light chains in clinical laboratory diagnostics.
Jenner E
Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
[TBL] [Abstract][Full Text] [Related]
16. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients.
Mellors PW; Dasari S; Kohlhagen MC; Kourelis T; Go RS; Muchtar E; Gertz MA; Kumar SK; Buadi FK; Willrich MAV; Lust JA; Kapoor P; Lacy MQ; Dingli D; Hwa Y; Fonder A; Hobbs M; Hayman S; Warsame R; Leung NR; Lin Y; Gonsalves W; Siddiqui M; Kyle RA; Rajkumar SV; Murray DL; Dispenzieri A
Blood Cancer J; 2021 Mar; 11(3):50. PubMed ID: 33664227
[TBL] [Abstract][Full Text] [Related]
17. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.
Mills JR; Kohlhagen MC; Dasari S; Vanderboom PM; Kyle RA; Katzmann JA; Willrich MA; Barnidge DR; Dispenzieri A; Murray DL
Clin Chem; 2016 Oct; 62(10):1334-44. PubMed ID: 27540026
[TBL] [Abstract][Full Text] [Related]
20. Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases.
Dasari S; Kohlhagen MC; Dispenzieri A; Willrich MAV; Snyder MR; Kourelis TV; Lust JA; Mills JR; Kyle RA; Murray DL
Mayo Clin Proc; 2022 Feb; 97(2):294-307. PubMed ID: 34887112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
